Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

The present invention provides a novel crystal of monosodium N-(2-ethylsulfonylannino-5-trifluoronnethyl-3-pyridyl)cyclohexane carboxamide that has a high density, particularly a high bulk density and/or tapped density, and that is suitable for formulation. More specifically, provided is an anhydrous crystal of monosodium N-(2-ethylsulfonylannino-5-trifluoronnethyl-3-pyridyl)cyclohexane carboxamide.

The present invention provides a novel crystal of monosodium N-(2-ethylsulfonylannino-5-trifluoronnethyl-3-pyridyl)cyclohexane carboxamide that has a high density, particularly a high bulk density and/or tapped density, and that is suitable for formulation. More specifically, provided is an anhydrous crystal of monosodium N-(2-ethylsulfonylannino-5-trifluoronnethyl-3-pyridyl)cyclohexane carboxamide.

Compounds of Formula I are disclosed and methods of treating viral infections with compositions comprising such compounds.

##STR00001##

Compounds of Formula I are disclosed and methods of treating viral infections with compositions comprising such compounds.

##STR00001##

Provided herein are synthetic methods for the preparation of compounds having the Formula: (I) and (I′) and salts thereof.

##STR00001##

The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated. ##STR00001##

The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated. ##STR00001##

The present invention relates to a compound of formula (I) wherein: wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are thought to be suitable for use as herbicides. The invention therefore also relates to a method of controlling weeds, especially grassy monocotyledonous weeds, in crops of useful plants, comprising applying a compound of formula (I), or a herbicidal composition comprising such a compound, to the plants or to the locus thereof.

##STR00001##

Provided herein are intermediates and processes useful for facile synthesis of compounds of Formula 2: ##STR00001##
wherein R.sup.1 is C(O)R.sup.2; R.sup.2 is alkyl optionally substituted with 1-5 halogens; G is phenyl or a 5-6 membered heteroaryl optionally substituted with 1-2 R.sup.3; and each R.sup.3 is independently C.sub.1-C.sub.6 alkyl, CN, C.sub.1-C.sub.6 alkyl-CN, 3-6 membered cycloalkyl, or 4-6 membered heterocycloalkyl.